Leaflet LENTULIL 4mg capsules

Indicated for: cancer

Route of administration: oral

Substance: lenvatinib (antineoplastic agent)

ATC: L01EX08 (Antineoplastic and immunomodulating agents | Protein kinase inhibitors | Other protein kinase inhibitors)

Precautions:
Fertility warning
Fertility warning

This medicine may affect fertility.

Dose adjustment in hepatic impairment
Dose adjustment in hepatic impairment

Dose adjustment may be needed in liver disease.

Cytotoxic / special handling
Cytotoxic / special handling

Handle with special care.

Contraception required
Contraception required

Effective contraception is required during treatment.

Contraindicated during breastfeeding
Contraindicated during breastfeeding

Do not use this medicine while breastfeeding.

Contraindicated during pregnancy
Contraindicated during pregnancy

Do not use this medicine during pregnancy.

Hepatotoxicity
Hepatotoxicity

This medicine may affect the liver.

Major drug interactions
Major drug interactions

This medicine may have important interactions with other medicines.

Myelosuppression / agranulocytosis
Myelosuppression / agranulocytosis

This medicine may lower blood cell counts.

Additional monitoring
Additional monitoring

This medicine is subject to additional monitoring.

Requires periodic laboratory tests
Requires periodic laboratory tests

Periodic laboratory tests may be required during treatment.

Severe skin reactions
Severe skin reactions

Stop taking the medicine and seek urgent medical help if a severe rash occurs.

Lenvatinib is a medication used to treat certain types of cancer, including thyroid cancer, hepatocellular carcinoma, and renal cancer. It is a tyrosine kinase inhibitor that works by blocking signals that promote tumor growth and the formation of new blood vessels.

The medication is taken orally, usually once daily, and the dosage is adjusted based on body weight and the type of cancer being treated. Treatment is carried out under the supervision of an oncologist.

Side effects may include high blood pressure, fatigue, diarrhea, loss of appetite, and abdominal pain. In rare cases, severe adverse effects such as liver or kidney failure may occur.

Patients should inform their doctor about any other medications they are taking and strictly follow the administration instructions. Pregnant or breastfeeding women should not use this medication.

General data about LENTULIL 4mg

  • Substance: lenvatinib
  • Date of latest medicines list: 01-01-2026
  • Product code: W71574001
  • Concentration: 4mg
  • Pharmaceutical form: capsules
  • Quantity: 30
  • Product type: Generic medicine
  • Prescription status: P-RF - Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.

Marketing authorisation

  • Manufacturer: SYNTHON HISPANIA S.L. - SPANIA
  • Holder: EGIS PARMACEUTICALS PLC - UNGARIA
  • Number: 16335/2025/01
  • Shelf life: 2 years

Concentrations available for lenvatinib

  • 10mg
  • 4mg